Navigation Links
Major Advance in the Observation of DNA Molecules
Date:12/7/2007

EVRY, France, December 7 /PRNewswire/ -- The teams of Eric Le Cam, from the "Molecular Interactions and Cancer" lab (UMR 8126 - Institut Gustave Roussy/CNRS/Universite Paris Sud) and David Pastre, from the "Structure and Activity of Normal and Pathological Biomolecules - SABNP" lab (Inserm/Universite d'Evry-Val-d'Essonne, U829, Genopole Evry) have successfully developed a new method for observing DNA using atomic force microscopy (AFM) under intracellular physico-chemical conditions. These findings, published in the Journal "Biomacromolecules" on November 19, 2007, were validated by the observation of various degrees of DNA compaction -- a key factor in replication and transcription. This method will facilitate research into DNA/protein interactions and their impacts on DNA activity, DNA chips and nanobiotechnology.

The first phase of these investigations was to find a method for absorbing DNA on a mica surface (a clay mineral traditionally used in biomolecular imaging), in the presence of monovalent salts. These findings, themselves representing a major advance in current techniques, make it possible to observe DNA molecules using atomic force microscopy (AFM) under intracellular physico-chemical conditions (molecular crowding, monovalent salts). Until recently, it was in fact impossible to obtain nanometric 3D high resolution images of DNA molecules using AFM under such lifelike conditions.

To validate this method and demonstrate the relevance of these novel imaging conditions, researchers chose to examine how macromolecular crowding affected the compaction of DNA molecules. The presence of very large molecules in the intracellular environment impacts directly the degree of DNA compaction, and thus its activity. This phenomenon, which is well-known among biologists, but poorly studied has a critical influence on replication, transcription and, consequently, on gene expression.

This method enables the observation of DNA molecules in various physiological conditions, in particular in interaction with proteins; it can also be used in the fields of DNA chips or nanobiotechnology.

Reference: "Atomic Force Microscopy Imaging of DNA under Macromolecular Crowding Conditions"

David Pastre, Loic Hamon, Alain Mechulam, Isabelle Sorel, Sonia Baconnais, Patrick Curmi, Eric Le Cam, Olivier Pietrement, Biomacromolecules, 2007, Nov 19.

Genopole(R)

Genopole(R) is France's first biopark dedicated to research into genetics and biotechnology. The campus is home to private and public research laboratories, biotech companies as well as university teaching facilities (University of Evry Val d'Essonne). With 21 research labs on campus and a portfolio of 62 biotech companies, therapeutic innovation is the core concern of Genopole(R) stakeholders. Its objective is to promote the development of research into genomics, post-genomics and related sciences and transfer technology to the industrial sector, develop advanced learning in these areas, and create and support biotech companies. http://www.genopole.fr


'/>"/>
SOURCE Genopole
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... PharmMD CEO Robert Yeager announced ... on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include ... data breaches for the Part D Star Rating improvement and Medication Therapy Management ...
(Date:2/11/2016)... ... 11, 2016 , ... AccuVein Inc. announces the Infusion Nurses ... Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ), ... market, facilitates adherence to this standard with its easy to use, widely deployed ...
(Date:2/11/2016)... ... , ... The annual list showcases the 20 Most Promising SharePoint Solution Providers ... and commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s ... recognize and promote technology entrepreneurship. , The survey was made at the end ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan Scientific, LLC, ... used in physical therapy, occupational therapy and sports medicine clinics, hospitals, universities and ... and therapy, introduces its new microFET Digital Pinch Gauge. , Hoggan Scientific ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led ... rates of several common cancer screenings, especially among women. Cancer screenings are often ... rates. , The study,“What Does Medicaid Expansion Mean for Cancer Screening and ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. ... utilizing human amniotic membrane and other birth tissues, human ... to develop and market advanced products and therapies, announced ... Markets, 2016 Global Healthcare Conference in New ... and CEO, Michael J. Senken , Chief Financial ...
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... to announce the acquisition of SolutionsRx, a full-service 340B ... hospitals. Along with providing traditional contract pharmacy services, SolutionsRx ... assist clients in navigating the complex 340B regulatory environment. ... Wellpartner. --> James R. Love , CEO ...
(Date:2/11/2016)... , Feb. 11, 2016  Proliant Biologicals is proud ... Serum Albumin (BSA) manufacturing facility.  The facility is located ... , in Feilding. Boone ... to functionally duplicate the systems in the U.S. facility, ... used for U.S. installations.  --> ...
Breaking Medicine Technology: